<a href="https://www.fiercebiotech.com/biotech/it-looks-hypothesis-will-pan-out-cullinan-builds-case-autoimmune-tces" hreflang="en">‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs</a>
Cullinan Therapeutics has presented promising data from its phase 1b trial of CLN-978, a CD19xCD3-directed T-cell engager, showing significant B-cell depletion in patients with autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. The findings suggest that T-cell engagers could effectively treat autoimmune conditions, potentially overcoming limitations faced by traditional CAR-T therapies.
Cullinan Therapeutics' phase 1b data on their CD19xCD3-directed T-cell engager (TCE), CLN-978, suggests that TCEs could emerge as a viable off-the-shelf option for treating autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), offering a scalable alternative to autologous CAR-T therapies. The study showed promising results in B-cell depletion and disease activity reduction with a favorable safety profile, positioning Cullinan's TCEs as a compelling candidate for further development and potential market entry in the autoimmune space.